

CHAPTER 11

End Stage Kidney Disease in Māori patients in Aotearoa/New Zealand

Reporting the incidence, prevalence and survival in Māori patients of Aotearoa/New Zealand receiving renal replacement therapy.

Contents

Executive Summary	2
Suggested Citation	2
New Patients	3
Primary Renal Disease	4
Incidence Rates	4
Prevalent Patients	6
Incidence and Prevalence per Population	7
Transplantation	8
Transplant Survival	10
Dialysis	12
Timing of Renal Replacement Therapy Initiation	13
Late Referral	13
Vascular Access	13

Executive Summary

In this chapter, the rates, practice patterns and outcomes of treatment for end-stage kidney disease for people identifying as Māori living in Aotearoa New Zealand are reported. Self-identified ethnicity is reported by renal units on behalf of patients.

Denominator population statistics are stratified by ethnicity. For example, the incidence of Renal Replacement Therapy (RRT) for Māori includes the national Māori population as the denominator. The denominator population is derived from the mid-year population (30 June) estimated each year by Statistics New Zealand from the Census (currently 2018). Denominator populations are not age-standardised in this report. Notably, Māori and non-Māori, non-Pasifika populations possess different age structures: Māori tend to be younger and demonstrate onset of long-term conditions at ages 10-20 years younger than non-Māori, non-Pasifika.

Overall, the disparity in the incidence rates of end-stage kidney disease for Māori patients are markedly and persistently higher than those for non-Māori, non-Pasifika patients. They experienced later referrals to specialist nephrology services and Māori patients had a higher use of facility dialysis as the principal modality of care, and lower use of each of the home-based modalities compared with non-Māori, non-Pasifika patients. Māori also continue to have significantly lower rates pre-emptive kidney transplantation.

Suggested Citation

ANZDATA Registry. 42nd Report, Chapter 11: End Stage Kidney Disease in Māori patients in Aotearoa New Zealand. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2019. Available at: http://www.anzdata.org.au

New Patients

A total of 187 patients identifying as Māori commenced treatment for end-stage kidney disease in 2018, representing 31% of all patients starting renal replacement therapy. The rate of haemodialysis commencement in non-Māori, non-Pasifika patients was 4-fold lower than for Māori. Māori were more likely to commence dialysis with haemodialysis than peritoneal dialysis compared with non-Māori, non-Pasifika patients (figure 11.1). Two Māori patients received a pre-emptive kidney transplant during 2018. In the last 5 years, 6 Māori patients have received a pre-emptive kidney transplant compared with 111 non-Māori, non-Pasifika patients.

Year	Modality	Māori	Non-Māori, non-Pasifika
2014	HD	110 (157)	134 (39)
2014	PD	51 (73)	107 (31)
2014	Graft	0 (0)	20 (6)
2015	HD	121 (170)	127 (36)
2015	PD	52 (73)	128 (36)
2015	Graft	0 (0)	22 (6)
2016	HD	108 (149)	144 (40)
2016	PD	61 (84)	116 (32)
2016	Graft	2 (3)	20 (6)
2017	HD	122 (166)	147 (40)
2017	PD	64 (87)	115 (31)
2017	Graft	2 (3)	21 (6)
2018	HD	106 (142)	132 (35)
2018	PD	79 (106)	109 (29)
2018	Graft	2 (3)	28 (7)

Table 11.1 New Patients (pmp) New Zealand 2014-2018

Figure 11.1 - Percentage of New Patients Commencing on Haemodialysis - New Zealand



Primary Renal Disease

The primary renal diseases of incident New Zealand patients over 2014-2018 are shown in table 11.2. Māori experience diabetic nephropathy at a substantially higher rate than non-Māori, non-Pasifika patients.

Primary Renal Disease	Māori	Non-Māori, non-Pasifika	
Diabetic Nephropathy	616 (70%)	382 (28%)	
Glomerulonephritis	123 (14%)	344 (25%)	
Hypertension	40 (5%)	176 (13%)	
Polycystic Disease	11 (1%)	111 (8%)	
Reflux Nephropathy	8 (1%)	48 (4%)	
Other	59 (7%)	241 (18%)	
Uncertain	19 (2%)	61 (4%)	
Not reported	4 (<1%)	7 (1%)	
Total	880	1370	

Table 11.2 Primary Renal Disease of New Patients New Zealand 2014-2018

Incidence Rates

Overall, the incidence rates (per million of population) of end-stage kidney disease for Māori patients are markedly and persistently higher than those for non-Māori, non-Pasifika patients. The disparity is confounded and underestimated by the age distributions of each population - Māori populations are considerably younger.

Although rates fluctuate from year to year, the incidence rates have been stable in recent years (figure 11.2). The relative rate differs with age - this is illustrated in figure 11.3.





Among Māori, disparities in the incidence of end-stage kidney disease from non-Māori, non-Pasifika persons occur as early as ages 15 to 24 years and are evident across all age groups (figure 11.3). There is no indication of gender differences in incidence rates for Māori.

Figure 11.3 - Relative Incidence Rate of Treated ESKD for Māori Patients compared with non-Māori, non-Pasifika Patients by Gender -New Zealand 2014-2018



Age specific trends in renal replacement therapy practices for Māori are shown in figure 11.4; note that the Y axis scales vary.









Prevalent Patients

The number of prevalent Māori patients with treated end-stage kidney disease continues to rise year-on-year (table 11.3 and figures 11.5 and 11.6). From 2016 to 2018, there were notable increases in the numbers of Māori people receiving peritoneal dialysis and with a kidney transplant.

-rable + r.5 + revalence + allerits by Eurineity and resalinent would be zearang zero $+ zero$
--

Year	Modality	Māori	Non-Māori, non-Pasifika
	HD	611 (59%)	684 (28%)
	% HD at home	23%	33%
2014	PD	269 (26%)	434 (18%)
	Тх	160 (15%)	1361 (55%)
	HD	637 (61%)	698 (27%)
201E	% HD at home	22%	31%
2015	PD	230 (22%)	438 (17%)
	Тх	174 (17%)	1408 (55%)
2016	HD	662 (61%)	699 (27%)
	% HD at home	21%	29%
	PD	232 (21%)	449 (17%)
	Тх	193 (18%)	1450 (56%)
	HD	658 (59%)	680 (26%)
2017	% HD at home	21%	28%
2017	PD	254 (23%)	440 (17%)
	Тх	207 (18%)	1505 (57%)
	HD	649 (57%)	700 (26%)
	% HD at home	20%	27%
2010	PD	268 (23%)	423 (16%)
	Тх	225 (20%)	1541 (58%)

Figure 11.5.1 - Prevalent Patients by Modality - New Zealand – Māori









Incidence and Prevalence per Population





Figure 11.8 - Incidence of New Transplants - New Zealand



Figure 11.9 - Prevalent Haemodialysis Patients - New Zealand



Figure 11.10 - Prevalent Peritoneal Dialysis Patients - New Zealand



Figure 11.11 - Prevalent Transplant Patients - New Zealand



0.

2014

2015

2016

Transplantation

20'15

2016

2017

2018

500

400

300

200

100

0

2014

Transplants per million population

The numbers of transplant recipients over the last 10 years are shown in table 11.4 by ethnicity and donor type. Figure 11.13 shows the transplant rate of dialysed patients aged 15-64, using dialysis time as the denominator, which illustrates that Māori patients receive a kidney transplant at a much lower rate than Non-Māori, non-Pasifika patients. Information on donor source is shown in figure 11.14 and trends are shown in figure 11.15. Living donor rates have increased for Māori patients since 2013, with increases in living unrelated donors.

Table 11 A Number of Trans	enlant Pocinionte	(nmn) by Ethnicit	v New Zeeland 2000-2018
	spiant Recipients	(ρπρ) by εππισι	y New Zealallu 2009-2010

Non-Māori, non-Pasifika

Year	Donor Type	Māori	Non-Māori, non-Pasifika
2009	DD	10 (15)	39 (12)
	LD	8 (12)	58 (17)
	Total	18 (27)	97 (29)
	DD	13 (20)	32 (10)
2010	LD	7 (11)	49 (15)
	Total	20 (30)	81 (24)
	DD	15 (22)	39 (12)
2011	LD	6 (9)	49 (14)
	Total	21 (31)	88 (26)
	DD	11 (16)	37 (11)
2012	LD	4 (6)	49 (14)
	Total	15 (22)	86 (25)
2013	DD	5 (7)	45 (13)
	LD	4 (6)	53 (16)
	Total	9 (13)	98 (29)
2014	DD	13 (19)	44 (13)
	LD	9 (13)	56 (16)
	Total	22 (31)	100 (29)
2015	DD	13 (18)	44 (12)
	LD	15 (21)	54 (15)
	Total	28 (39)	98 (28)
2016	DD	12 (17)	57 (16)
	LD	13 (18)	56 (16)
	Total	25 (35)	113 (31)
2017	DD	17 (23)	70 (19)
	LD	6 (8)	51 (14)
	Total	23 (31)	121 (33)
	DD	15 (20)	65 (17)
2018	LD	14 (19)	54 (14)
	Total	29 (39)	119 (32)

Non-Māori, non-Pasifika

2018

2017

Figure 11.13 - Transplant Rate of Dialysed Patients by Ethnicity 2009-2018 - New Zealand, Patients Aged 15-64



The number of transplants to Māori recipients increased since 2013, through a higher proportion of transplants from living donors, however, there are ongoing disparities in the rate of transplants between Māori and the non-Māori non-Pacifika population.





Figure 11.15 - Donor Type by Ethnicity and Year - New Zealand





Transplant Survival

There is a small difference in survival after kidney transplantation from a deceased donor between Māori and non-Māori, non-Pasifika recipients, which is apparent from 6 months after transplantation. At 5 years after kidney transplantation from a deceased donor, 88% of Māori recipients and 91% of non-Māori, non-Pasifika recipients were alive (figure 11.17).





Over the first 5 years after kidney transplant from a deceased donation, some kidney transplants have been lost either through the transplant failing or the patient dying with a functioning kidney. Over the first three years, there was no difference in the proportions of Māori and non-Māori, non-Pasifika recipients who experienced graft loss. Transplant kidney function at 5 years post-transplant was recorded in 77% of Māori recipients compared with 85% of non-Māori, non-Pasifika persons (figure 11.18).



Cumulative incidence curves (utilising competing risk techniques to account for the effects of both components of graft loss, ie graft failure and death with a functioning graft) are shown for Māori transplant outcomes in figure 11.19.

For Māori patients, mortality is increased immediately after transplantation, while rates of graft failure, at least in the first 3 years, appears to be comparable with non-Māori, non-Pasifika patients.

Figure 11.19 - Transplant Outcomes, New Zealand - Primary Deceased Donor Kidney-only Transplants 2009-2018



Dialysis

The distribution of dialysis modality is shown graphically in figure 11.20. Māori patients had a higher use of facility dialysis as the principal modality of care, and lower use of each of the home-based modalities. For non-Māori, non-Pasifika patients, over half underwent home-based care. The proportion of Māori patients receiving home-based dialysis was approximately 10% lower.



Figure 11.20 - Dialysis Modality End 2018 - New Zealand, by Ethnicity

Half of the people who started dialysis over 2009-2018 were alive 5 years later (figure 11.21). Non-Māori-non-Pasifika and Māori cohorts experienced similar survival over 5 years after starting dialysis, although it is possible that differences between populations including age distribution and access to competing treatments (transplantation) may have impacted mortality estimates.

Figure 11.21 - Incident Dialysis Patient Survival 2009-2018 - New Zealand



Timing of Renal Replacement Therapy Initiation

In Aotearoa New Zealand, the level of kidney function at which dialysis was commenced ranged between eGFR 5-7 mL/min/1.73m² for Māori patients and 6-8 mL/min/1.73m² for non-Māori, non-Pasifika patients.

Figure 11.22 - eGFR at RRT start - New Zealand



Late Referral

The proportion of patients who experienced late referral to specialist nephrology services in Aotearoa/New Zealand over 2014-2018 is shown in table 11.5. Late referral is becoming more common in Māori and less common in non-Māori, non-Pasifika patients.

Table 11.5 Percentage of Late Referral by Ethnicity New Zealand 2014-2018

Year	Māori	Non-Māori, non-Pasifika
2014	8%	14%
2015	16%	13%
2016	13%	13%
2017	13%	11%
2018	15%	11%

Vascular Access

Incident Vascular Access

Incident vascular access data are presented in table 11.6, and prevalent data in table 11.7.

The proportion of Māori patients commencing RRT with haemodialysis using a catheter rather than permanent access was similar to that in non-Māori, non-Pasifika patients in 2018 (table 11.6).

Table 11.6 Incident Vascular Access New Zealand 2014-2018

Year	Vascular access	Māori	Non-Māori, non-Pasifika
2014	AVF	41 (37%)	38 (28%)
	AVG	2 (2%)	2 (1%)
2014	CVC	65 (59%)	94 (70%)
	Not reported	2 (2%)	0 (0%)
	AVF	34 (28%)	34 (27%)
2015	AVG	3 (2%)	2 (2%)
2015	CVC	81 (67%)	88 (69%)
	Not reported	3 (2%)	3 (2%)
2016	AVF	31 (29%)	34 (24%)
	AVG	0 (0%)	1 (1%)
	CVC	75 (69%)	106 (74%)
	Not reported	2 (2%)	3 (2%)
	AVF	30 (25%)	32 (22%)
2017	AVG	3 (2%)	2 (1%)
2017	CVC	88 (72%)	113 (77%)
	Not reported	1 (1%)	0 (0%)
0040	AVF	22 (21%)	30 (23%)
	AVG	0 (0%)	2 (2%)
2010	CVC	84 (79%)	100 (76%)
	Not reported	0 (0%)	0 (0%)

Prevalent Vascular Access

In contrast to incident vascular access, the rate of catheter use for prevalent dialysis patients is lower for Māori patients in 2018 than non-Māori, non-Pasifika patients (table 11.7).

Table 11.7 P	revalent Vascu	lar Access New	Zealand 2014-2018

Year	Vascular access	Māori	Non-Māori, non-Pasifika
	AVF	457 (75%)	459 (67%)
	AVG	29 (5%)	36 (5%)
2014	CVC	117 (19%)	169 (25%)
	Not reported	8 (1%)	20 (3%)
	AVF	428 (67%)	453 (65%)
201 <i>E</i>	AVG	35 (5%)	27 (4%)
2015	CVC	140 (22%)	183 (26%)
	Not reported	34 (5%)	35 (5%)
2016	AVF	452 (68%)	446 (64%)
	AVG	27 (4%)	27 (4%)
	CVC	167 (25%)	204 (29%)
	Not reported	16 (2%)	22 (3%)
	AVF	448 (68%)	423 (62%)
2017	AVG	26 (4%)	20 (3%)
2017	CVC	175 (27%)	222 (33%)
	Not reported	9 (1%)	15 (2%)
	AVF	438 (67%)	419 (60%)
2018	AVG	21 (3%)	17 (2%)
2010	CVC	176 (27%)	248 (35%)
	Not reported	14 (2%)	16 (2%)

Patient Flow

Table 11.8 shows the overall patient flow in New Zealand by ethnicity. Notably, mortality for Māori patients is 3 to 4-fold higher per million of population.

Table 11.8 Patient Flow (pm	p) New Zealand 2014-2018
-----------------------------	--------------------------

Year	Event	Māori	Non-Māori, non-Pasifika
2014	New patients	161 (229)	261 (76)
	New transplants	22 (31)	100 (29)
	Pre-emptive transplants	0 (0)	20 (6)
	Prevalent dialysis	880 (1254)	1118 (324)
	Prevalent transplants	160 (228)	1361 (394)
	Total prevalence	1040 (1482)	2479 (717)
	Deaths	126 (180)	220 (64)
2015	New patients	173 (243)	277 (79)
	New transplants	28 (39)	99 (28)
	Pre-emptive transplants	0 (0)	22 (6)
	Prevalent dialysis	867 (1217)	1136 (323)
	Prevalent transplants	174 (244)	1408 (400)
	Total prevalence	1041 (1462)	2544 (722)
	Deaths	176 (247)	203 (58)
2016	New patients	171 (236)	280 (78)
	New transplants	25 (35)	113 (31)
	Pre-emptive transplants	2 (3)	20 (6)
	Prevalent dialysis	894 (1236)	1148 (319)
	Prevalent transplants	193 (267)	1450 (403)
	Total prevalence	1087 (1503)	2598 (722)
	Deaths	132 (182)	221 (61)
2017	New patients	188 (256)	283 (77)
	New transplants	23 (31)	121 (33)
	Pre-emptive transplants	2 (3)	21 (6)
	Prevalent dialysis	912 (1242)	1120 (304)
	Prevalent transplants	207 (282)	1505 (409)
	Total prevalence	1119 (1524)	2625 (713)
	Deaths	156 (212)	250 (68)
2018	New patients	187 (251)	269 (72)
	New transplants	29 (39)	119 (32)
	Pre-emptive transplants	2 (3)	28 (7)
	Prevalent dialysis	917 (1231)	1123 (299)
	Prevalent transplants	225 (302)	1541 (411)
	Total prevalence	1142 (1533)	2664 (710)
	Deaths	168 (226)	219 (58)

Cause of Death

The causes of death in 2018 are shown in figure 11.23 and table 11.9, categorised by ethnicity and modality at time of death.

For Māori, the most common cause of death amongst those who died while receiving dialysis was cardiovascular disease.

Among non-Māori, non-Pasifika dialysis patients, withdrawal from dialysis was the most common cause of death.

Dialysis Transplant

Figure 11.23 - Cause of Death by Modality and Ethnicity, New Zealand - Deaths Occurring During 2018

Cardiovascular

Infection

Table 11.9 Cause of Death by Modality and Ethnicity, New Zealand 2018

Modality	Cause of death	Māori	Non-Māori, non-Pasifika
	Cardiovascular	64 (40%)	50 (29%)
	Withdrawal	31 (19%)	52 (30%)
	Cancer	4 (3%)	6 (3%)
Dialysis	Infection	17 (11%)	16 (9%)
	Other	40 (25%)	46 (27%)
	Not reported	4 (3%)	2 (1%)
	Total	160	172
	Cardiovascular	1 (17%)	13 (31%)
	Withdrawal	0 (0%)	3 (7%)
	Cancer	0 (0%)	10 (24%)
Transplant	Infection	1 (17%)	7 (17%)
	Other	4 (67%)	9 (21%)
	Not reported	0 (0%)	0 (0%)
	Total	6	42

Withdrawal

Other

Cancer

Not reported